JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

30.51 4.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.52

Максимум

30.92

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+65.91% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	122M 3B
Предишно отваряне	25.74
Предишно затваряне	30.51

Настроения в новините

By Acuity

27%

73%

82 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2026 г., 23:33 ч. UTC

Горещи акции

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28.04.2026 г., 23:24 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28.04.2026 г., 22:46 ч. UTC

Печалби

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28.04.2026 г., 22:37 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28.04.2026 г., 22:15 ч. UTC

Печалби

Значими събития в новините

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28.04.2026 г., 23:19 ч. UTC

Пазарно говорене

Печалби

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28.04.2026 г., 23:09 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees One Rate Rise to 4% in Benign Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28.04.2026 г., 22:51 ч. UTC

Печалби

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28.04.2026 г., 22:40 ч. UTC

Пазарно говорене

Значими събития в новините

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28.04.2026 г., 22:32 ч. UTC

Печалби

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28.04.2026 г., 22:22 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28.04.2026 г., 22:07 ч. UTC

Пазарно говорене

Значими събития в новините

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

65.91% нагоре

12-месечна прогноза

Среден 48.38 USD 65.91%

Висок 80 USD

Нисък 24.18 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

82 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.